Paradigm Health closed an oversubscribed $78 million Series B round led by ARCH Venture Partners, with participation from DFJ Growth and existing backers including F-Prime, General Catalyst, GV, Lux Capital, and Mubadala Capital. The company, which supports Phase I–III oncology studies for 15 of the world’s 20 largest pharmaceutical manufacturers, plans to use the new capital to scale its trial platform as demand rises among biopharma firms and health systems seeking more efficient research operations.
Robert Nelsen, Managing Partner at ARCH Venture Partners, said, “When trials run more efficiently, new treatments reach patients sooner,” adding that Paradigm Health is building the infrastructure needed to help hospitals and sponsors conduct studies “faster, more intelligently, and at far lower cost.”
Following its acquisition of Flatiron Health’s Clinical Research Business, Paradigm Health now operates the largest oncology research network in the U.S., spanning 45 states, 166 provider organizations, and 2,100 care locations, giving 70% of U.S. cancer patients proximity to trial sites. CEO Kent Thoelke noted, “Patients in community and rural settings have limited access to trials, and their experiences remain underrepresented in research.” Paradigm’s AI-enabled system automates patient matching and site feasibility, enabling health systems to enroll participants as much as four times faster while reducing administrative strain.
